This article has been updated with comments from Wells Fargo and corrected to acurately reflect the expected Q4 and FY 2015 EPS figures.

NEW YORK (GenomeWeb) – Qiagen today reported preliminary earnings for the fourth quarter and fiscal year 2015 that fell short of management's outlook and analyst expectations. The firm also reported a previously undisclosed acquisition of sample prep firm Mo Bio Laboratories.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.